Uncategorized
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), an innovative biotechnology company, has set its sights on using its proprietary drug delivery technology to provide an alternative method of nicotine ingestion that is safer than smoking. An article further discussing the company reads, “The technology, known as DehydraTECH(TM), is a patented, cost-effective delivery mechanism that has been shown to improve the ingestibility of cannabinoids, vitamins, nonsteroid anti-inflammatory drugs (NSAIDs) and nicotine. Now, Lexaria has partnered with one of the world’s largest tobacco firms to develop new, reduced-risk, oral nicotine products using the technology (http://nnw.fm/8brW8). . . . The deal funds Lexaria’s R&D program — and consumer product development — in exchange for certain DehydraTECH license rights and a minority equity interest in Lexaria Nicotine, a wholly owned subsidiary of Lexaria Bioscience Corp. An initial tranche of $1 million has been provided, with additional phases providing up to $12 million total. Lexaria has granted a license for its technology to be used in nicotine-based, oral-format products on an exclusive basis in the United States and a nonexclusive basis elsewhere globally, for which it will receive royalties on every dollar of revenue generated utilizing its technology.”
To view the full article, visit: http://nnw.fm/XsU4k
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in more than 40 countries around the world and has patents granted in the United States and in Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://nnw.fm/LXRP
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
September 13, 2019
An audit done by a marijuana business association has revealed that the number of black market cannabis industry players is thrice the number of the licensed marijuana businesses in the state.
The audit, whose findings were made public on Wednesday, indicates that there are 2,835 illegal marijuana businesses operating within California while the statistics from the Bureau of Cannabis Control show that only 873 companies are licensed to conduct marijuana-related business activities within the state.
This means that the number of illicit players dwarfs those who are within the licensed marijuana space. The audit was done by an industry group called the United Cannabis Business Association.
Their findings are the latest indicator of how rocky the marijuana industry in California is, even at a time when the state promised that it was going to crack the whip on the black market starting in 2018.
Earlier this year, a financial audit backed by industry players estimated that approximately $8.7 billion was lost to unlicensed cannabis products in the state while licensed businesses sold marijuana products worth only $3.1 billion.
Such information has led players in the legal marijuana industry to put their elected leaders, law enforcement and industry regulators on the spot for failing to curb the illicit trade of marijuana within the state.
This frustration with the slow progress in dealing with the marijuana black market has even prompted some licensed marijuana businesses in Los Angeles to recommend that tougher measures, such as prosecuting offenders in federal courts and incarcerating them thousands of miles away from their homes, could be tried to send a strong message that illegal commercial marijuana activities wouldn’t be tolerated or handled with kid gloves.
However, California’s marijuana industry isn’t faced with only the black market as a stumbling block. The industry is also grappling with the bans imposed on marijuana business operations by most of the local authorities.
The bans have put the state and the local authorities on a collision course since the state says that marijuana deliveries can be made anywhere within the state while the local authorities insist that the law allows them to either accept or ban marijuana companies from operating within their jurisdictions.
This conflict may also be fueling the marijuana black market since there are people who would wish to access marijuana in those areas where cannabis businesses aren’t allowed to operate, and where there is a need, supply will always show up one way or the other.
It isn’t clear what experienced industry actors like Neutra Corp. (OTCQB: NTRR) and Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) would propose as a comprehensive way to fix the major problems facing the largest marijuana market in the U.S.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
- Feedback from retailers confirms premium organic segment highly in demand
- Price premium not a barrier for cannabis consumers looking for high-quality
- TGOD’s high-THC strain, Unite Organic, performing well in premium segment with positive consumer feedback
- Company already received second order from the OCS as some retailers quickly sold out
TORONTO, Sept. 12, 2019 – The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) (US:TGODF), a leading producer of premium certified organic cannabis, is pleased to announce that following its launch in Ontario at the end of August, which marked the Company’s entrance into Canada’s recreational market, initial demand has exceeded expectations. TGOD’s high-THC signature strain, Unite Organic, is performing well online and at dispensaries, triggering a second order from the OCS earlier than initially anticipated.
“We are thrilled to witness such strong sales and positive feedback from retailers and consumers across Ontario, Canada’s most populous province at 14.32 million people. We can see from the initial response that demand for high-quality flower is strong,” commented Brian Athaide, CEO of TGOD. “Our team is working hard to ramp up production of our premium organic products as we get ready to expand distribution with additional strains and product forms as well as to other provinces in the months ahead. With our Hamilton hybrid greenhouse completed, and a second one nearing completion in Valleyfield, we are on track to distribute nationally early next year.”
As highlighted in a study conducted by Hill & Knowlton earlier this year, over 50% of recreational consumers who intended to purchase cannabis stated that it is important that their cannabis be organic. TGOD’s cannabis is grown in the Company’s proprietary living soil, in accordance with all-natural principles and without irradiation. The Company’s growing process is also certified organic by both Pro-cert and ECOCERT, two leading organic certification bodies, providing consumers with a safe, consistent, and enjoyable cannabis experience.
About The Green Organic Dutchman Holdings Ltd.
The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US: TGODF) is a publicly traded, premium global organic cannabis company, with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic hemp CBD oil operations in Canada, and through its wholly owned subsidiary HemPoland distributes premium hemp CBD oil in the EU. The Company grows high quality, certified organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned capacity of 219,000 kgs and is building 1,643,600 sq. ft. of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark.
TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.
For more information on The Green Organic Dutchman Holdings Ltd., please visit www.tgod.ca.
Forward-Looking Information Cautionary Statement
This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward looking statements in this release includes, but is not limited to, statements about the availability of the Company’s products at the Ontario Cannabis Store or other retailers, plans to offer certain products to various provinces, statements about future production capacity, statements about the receipt of any regulatory permits or licences, statements about the offering of any particular products by the Company in any jurisdiction and statements regarding the future performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.
The CBD story is exploding. At current pace, The Brightfield Group says CBD sales could explode to $23.7 billion by 2023. In fact, “The bulk of this growth is coming from large retailers like CVS, Walgreens, and Kroger entering the market and providing that availability to consumers,” says Brightfield Managing Director, Bethany Gomez. Already, major retailers are just beginning to embrace CBD thanks to sizable consumer demand. To date, Neiman Marcus, Sephora, Vitamin Shoppe, Kroger, Barney’s DSW, CVS, American Eagle, and Walgreen’s have all jumped at the opportunity. Even better, support for cannabis legalization is exploding. A Gallup survey found that 66% of Americans are in favor of legalization. That’s up from just 60% in 2016. That’s opening a wide range of opportunity for companies including The Yield Growth Corp. (CSE:BOSS) (OTC:BOSQF), Canopy Growth Corporation (TO:WEED) (NYSE:CGC), Green Growth Brands Inc. (CSE:GGB) (OTC:GGBXF), Charlotte’s Web Holdings Inc. (CN:CWEB)(OTC:CWBHF), and OrganiGram Holdings Inc. (TSX:OGI)(NASDAQ:OGI).The Yield Growth Corp. (CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWS: The Yield Growth Corp. just announced it has entered into an agreement with Peak Performance Products Inc., who will act as the wholesale distributor for Yield’s Urban Juve hemp products within the health retail channel across Canada. Peak Performance has more than 20 years’ experience representing global health and wellness brands in the Canadian marketplace. They provide the highest quality natural health products to reputable retailers across Canada, with access to a network of more than 3,500 brick-and-mortar and online retailers, in multiple channels, nationwide. The agreement grants Peak Performance rights to distribute and sell Urban Juve products at wholesale to health retailers across Canada. Peak Performance will actively promote the sale and distribution of the Urban Juve product line across Canada. They will maintain a complete line of products on hand to ensure prompt service of all retailers. The agreement was signed September 9, 2019 and has a two-year term.In addition to ongoing marketing efforts, Peak Performance also will feature Urban Juve products at their booth at the Canadian Health Food Association trade show in Toronto on September 14th and 15th. This event is Canada’s largest trade show dedicated to natural health, specialty and organic products, and the Peak Performance booth will showcase Urban Juve samples, demonstrations and product knowledge to local and international attendees. “Peak Performance is a top distributor in Canada and has successfully worked with the health and wellness industry for more than 20 years,” says Sandi Lesueur, President of Urban Juve. “They’ve chosen to distribute Urban Juve products because of their uniqueness: our Ayurveda-inspired, hemp-infused products are unlike anything on the market. Our booth is always the busiest when participating at trade-shows. I expect the same at this weekend’s CHFA event.”
Other cannabis-related developments from around the markets include:
Canopy Growth Corporation (TO:WEED)(NYSE:CGC) just announced that it has received a license from Health Canada for its KeyLeaf Life Sciences facility in Saskatoon, Saskatchewan. Including the Smiths Falls site and the recently licensed BC Tweed extraction site, Canopy Growth now operates three significant extraction assets to support the throughput required for large scale value-add product development. Canopy Growth recently retrofitted the now fully licensed KeyLeaf facility in Saskatchewan, a company with over 50 years of experience in the extraction industry. This facility is expected to be online in the Fall of 2019 and has the capacity to extract up to 5,000 kilograms of hemp or cannabis biomass per day. The application for the license was submitted under KeyLeaf’s previous name, POS Management Corp. and will be updated in due course. The newly licensed extraction platform is located in close proximity to Canopy Growth’s large-scale outdoor hemp and cannabis grow operations. The Company looks forward to the additional capacity increasing production efficiency, augmenting output volume, and ultimately reducing operational costs for value-add products set to be rolled out in the Canadian recreational and medical markets at the end of calendar year 2019. “With this milestone, we are executing against the vision of making strategic investments today in order to deliver results over the long term,” said Mark Zekulin, CEO, Canopy Growth. “This license will ensure we have the supply of extraction inputs for the medical, CBD, and recreational markets, especially the next generation of value-add, high margin cannabis products here in Canada.”
Green Growth Brands Inc. (CSE:GGB)(OTC:GGBXF) just announced that it will open 100th Seventh Sense Botanical Therapy mall-based shop. The first Seventh Sense shop opened in early February. “This is a huge milestone for Green Growth Brands and Seventh Sense,” said Peter Horvath, CEO of Green Growth Brands. “We believe we have created the largest and most valuable network of brick and mortar CBD shops in the country.” Seventh Sense shops retail high-quality botanical therapy CBD-infused personal care and beauty products at affordable prices. The product offering includes over 100 SKUs across bath, body, face, therapeutic, and sleep categories.
Charlotte’s Web Holdings Inc. (CN:CWEB)(OTC:CWBHF) just announced that Russell Hammer has joined the Company as Chief Financial Officer, effective tomorrow, August 15, 2019. Mr. Hammer, who has most recently served as an advisor in private equity investments, brings more than 30 years of finance experience in the retail, tourism and technology sectors. With his experience leading multi-billion-dollar multinational companies, he is the latest top-tier executive to join Charlotte’s Web as the Company accelerates its growth and evolution into a global consumer packaged goods (“CPG”) brand. Mr. Hammer replaces Rich Mohr, who as CFO has overseen the Company’s successful transition to a publicly traded company and market leader in hemp CBD products. “Russ’s appointment aligns perfectly to support the Company’s evolution over the past few years from an early stage organization to a leading public company, into its next phase transitioning to a global CPG company. His breadth of international finance experience across a range of industries, as well as expertise in building operational infrastructure, applying forward-looking analytics, M&A, and accessing capital markets will help us scale the business in a financially stable way,” said Deanie Elsner, CEO of Charlotte’s Web.
OrganiGram Holdings Inc. (TSXV:OGI)(NASDAQ:OGI) just announced it entered into an advance payment and purchase agreement with 703454 N.B. Inc. (carrying on business as 1812 Hemp) under which the Company will pre-fund hemp purchases to receive access to as much as 60,000 kilograms of dried hemp flower to be harvested in calendar 2019 for extraction into cannabidiol isolate. Organigram is already a party to a purchase agreement entered into in January 2019 with 1812 Hemp, in which Organigram was granted a right of first refusal on 1812 Hemp’s production of certain hemp cultivars. Access to CBD-rich hemp flower is being facilitated through the Payment Agreement as the Company will advance funds to 1812 Hemp for their purchase of specialized large-scale hemp harvesting and processing equipment to maximize crop yields, contribute to increased efficiency and improve preservation of harvested cannabinoids. Purchase conditions for the dried hemp flower continue to be governed by the January Purchase Agreement which secures supply and supports research and development on the genetic improvement of hemp through traditional plant breeding methods.
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with www.MarijuanaStox.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with www.MarijuanaStox.com, is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of MarijuanaStox.com) and The Yield Growth Corp, Winning Media has been paid four thousand five hundred dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please click here for full disclaimer.
Contact Information:
2818047972
ty@marijuanastox.com
September 12, 2019
The former head of the FDA has said that the conflict between the federal and state marijuana laws has created regulatory gaps which have given chance to tainted or substandard products to enter the market, resulting in the fatal lung injuries that have been reported recently. He hinted that federal action could put an end to this problem.
In a series of tweets, Scott Gottlieb said that the permissive marijuana laws of different U.S. states cause him a lot of worry since they give adults unfettered access to recreational marijuana and yet there are no federal regulations to oversee the production and manufacture of those marijuana products.
In tweets over the weekend, Dr. Gottlieb admitted that illicit vape cartridges, including those that may contain CBD and THC, seem to be behind the spate of lung problems that have so far killed five people and injured hundreds more across the country.
Experts are of the view that those vape cartridges may have contained ingredients not sanctioned for use in vape products (vitamin E acetate, for example) and those ingredients become deadly when they are inhaled.
In a TV appearance, the former FDA commissioner said that states legalize recreational marijuana when they don’t have the capacity to regulate the industry properly, while the federal government which has this needed capacity remains aloof since marijuana is a controlled substance. And when problems arise, states blame the federal government for those problems.
Gottlieb hinted that there is a need for the federal government to rethink its position on marijuana so that it can be possible for legitimate entities that wish to conduct research on the substance to do so.
Without saying marijuana should be federally legalized, Gottlieb’s statement about the need for federal oversight suggests as much because the FDA can only oversee an industry that is legal under federal law.
He also said that under the current legal regime, the FDA may be unable to regulate any vape pens that aren’t intended to be used by the tobacco industry. Making the necessary change would require congressional action, he added.
It appears as though the country is at the same point that it was decades ago just before the prohibition of alcohol ended. At that time, people died after consuming tainted alcohol sold on the black market, and a decision was made to legalize alcohol so that the industry could be legalized. Could the injuries and fatalities attributed to illegal vape cartridges be likely to result in the federal legalization of marijuana?
Analysts aren’t sure that industry players like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and Marijuana Company of America (OTCQB: MCOAD) can answer that question in the affirmative.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced its receipt of United States Patent and Trademark Office (“USPTO”) formal notice of allowance to Patent Application Serial No. 15/776,061. The patent, titled “CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NUCROSIS FACTOR,” covers INmune’s INB03 Program that utilizes dominant negative TNFα (“DN-TNFα”) technology for treating cancer. “This is an important patent for INmune Bio, Inc. and provides exclusivity for use of our DN-TNFα technology for the treatment of cancer,” INmune Bio Assoc. General Counsel Joshua Schoonover said in the news release. “With the approval from the USPTO, and the positive indication of allowable subject matter in the international preliminary report on patentability for the corresponding international PCT patent application, published as WO/2017/106278, we expect this patent family should develop into global intellectual property rights.”
To view the full press release, visit: http://nnw.fm/ULr9Z
About INmune Bio, Inc.
INmune Bio, Inc. is a clinical-stage immunology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing two product platforms, the DN-TNFα Platform and an Immune Priming Platform, as well as multiple products related to these platforms that reengineer the patient’s innate immune system’s response to disease. In addition to INB03, the DN-TNFα Platform includes XPRO1595, a DN-TNFα protein biologic that targets soluble TNFα (sTNFα) and may have many beneficial effects in patients with Alzheimer’s disease by decreasing neuroinflammation; and NeuLiv, also a DN-TNFα protein biologic that may enable targeting of the underlying cause of non-alcoholic steatohepatitis (NASH), to help stop the disease and allow the liver to heal. The Immune Priming Platform includes INKmune, which is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and neurodegenerative diseases. For more information, visit the company’s website at www.INmuneBio.com.
NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://nnw.fm/INMB
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
TORONTO, Sept. 11, 2019 – Canopy Rivers Inc. (“Canopy Rivers” or the “Company“) (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, is pleased to announce the formation of its Strategic Advisory Board, a group of respected business leaders that will provide guidance to Canopy Rivers’ executive team as it continues to build and strengthen the Company’s global portfolio of leading cannabis companies.
“We have assembled a group of outstanding individuals with exceptional track records as leaders in their respective industries,” said Narbe Alexandrian, President and CEO of Canopy Rivers. “The Strategic Advisory Board will play an important role in providing guidance and insight to Canopy Rivers as we pursue our global growth strategy. Together, we look forward to building the cannabis industry of tomorrow, today.”
Inaugural members of Canopy Rivers’ Strategic Advisory Board include:
John Ruffolo – Mr. Ruffolo is the Co-founder and Vice Chair of the Council of Canadian Innovators. Mr. Ruffolo founded OMERS Ventures and also formed Platform Investments, OMERS’ innovation arm, where he led investments in Purpose Financial, PointNorth Capital, District Ventures, OneEleven and ArcTern Ventures. He sits on several boards, including Ether Capital, Ontario Centres of Excellence, and the Royal Ontario Museum.
Meg Lovell – Ms. Lovell served as Co-Head of M&A and as Corporate and Commercial Counsel at Imperial Brands PLC, a global consumer goods company with a portfolio of next-generation and tobacco products. During her time at Imperial Brands, Ms. Lovell led a number of strategic transactions with a particular focus on Imperial Brands’ next-generation product portfolio, in addition to advising on an extensive range of matters across the organization. Prior to joining Imperial Brands, Ms. Lovell was an Associate at Slaughter and May, a leading multinational law firm.
Philip Donne – Mr. Donne is a board advisor for several companies including Greenhouse Juice, Longo’s, Nature’s Path Foods, and Valens. He is the former President of Campbell Canada, the former President and CEO of Kellogg Canada, and the former President of Cossette’s Toronto office and Co-President of the agency’s Montreal Office. An award-winning marketing strategist, Mr. Donne received the Gold Medal Award from the Association of Canadian Advertisers and a Golden Pencil Award for his contributions to the Canadian food industry.
Canopy Rivers would also like to announce that Daniel Pearlstein, EVP, Strategy, is no longer with the Company. The Company would like to thank Mr. Pearlstein for his contributions to the Company and wishes him well with his future endeavors.
About Canopy Rivers:
Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.
Forward-Looking Statements
This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Canopy Rivers with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding: the role of the Company’s Strategic Advisory Board; the Company’s future plans and global growth strategy; and expectations for other economic, business, and/or competitive factors.
Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Canopy Rivers believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of Canopy Rivers. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; changes in the role of the Strategic Advisory Board or the Company’s plans and growth strategy; the ability of the Company and the Strategic Advisory Board to collaborate; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in Canopy Rivers’ annual information form dated July 15, 2019, filed with the Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Canopy Rivers has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Canopy Rivers does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
September 11, 2019
Palm Beach, FL –September 11, 2019 – Recent advances in marijuana technology have changed the industry. From cultivation to consumption, technology is improving the end product and using new farming techniques to produce better strains. A recent article on the cannabis industry’s evolution said: “The cannabis industry is on a tremendous upswing, with numbers expected to reach $31.4 billion by the year 2021 (this according to Grand View Research, a cannabis market research firm). One of the factors that is pushing the industry ever upwards is a surge in marijuana technology that’s helping produce better crops, ensure the highest safety standards, connect consumers and cannabis businesses, and provide a variety of new options for consumption.” Active companies in the industry making moves to ready that include: GreenStar Biosciences Corp. (CSE: GSTR), The Yield Growth Corp. (OTCQB: BOSQF) (CSE: BOSS), The Supreme Cannabis Company, Inc. (OTCQX: SPRWF) (TSX: FIRE), OrganiGram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), MedMen Enterprises Inc. (OTCQX: MMNFF) (CSE: MMEN).
They continued saying: “The world of cannabis technology is fast-paced and ever-changing… As with all the other fields in the agriculture industry, cannabis cultivation has benefitted from the evolution of marijuana technology over the years. Marijuana growers are constantly finding new ways to grow more robust crops in less space and with less labor required.”
GreenStar Biosciences Corp. (CSE:GSTR) BREAKING NEWS: GreenStar Biosciences, a growth-oriented technology and services company that provides real estate, financial, management and other support to licensed cannabis businesses in the United States, is pleased to announce that it has received positive results from an initial cultivation test involving the growth of approximately 2,500 plants using the proprietary patent-pending grow and cultivation technology of Progressive Herbs Inc. (“Progressive”). As previously announced, Capri PHGS LLC (“Capri”), a 50/50 joint venture between the Company and Progressive, holds the exclusive license to utilize Progressive’s proprietary cultivation technology. The Company also received results from independent laboratory testing on the three strains used in the initial cultivation test, which demonstrated total cannabinoid percentages between 22.85% to 32.54%, depending on the strain tested.
Seeds from three different proprietary (by agreement) strains were planted inside a 200-square-foot room at Cowlitz County Cannabis Cultivation Inc.’s warehouse facilities in Washington State. The results of this initial cultivation test appear to validate several efficiencies and advantages of the proprietary cultivation technology compared to traditional greenhouse operations:
- High total cannabinoid levels:
- Higher than normal total cannabinoid percentages of three strains tested (22.85%, 30.61% and 32.54% (compared to industry averages of between approximately 15-23% for similar strains).
- No use of pesticides, herbicides or fungicides.
- Free of heavy metals and contaminants.
- Lower operational costs::
- Room used for the initial cultivation test was readied for seed planting in two weeks, using “off-the-shelf” environmental control products.
- Preliminary evidence that plants can be grown in a sub-optimal space with minimal, low-cost equipment.
- Lower electricity costs (initial testing showed production of approximately 3 grams per watt used compared to industry average of 1-1.5 grams per watt).
- Faster harvest time:
- All plants were harvested in approximately 72 days, allowing for up to five harvest cycles per year (compared to an average of three to four per year for a traditional indoor grow operation).
Independent laboratory testing on random flower samples of the harvested plants was conducted by Praxis Laboratory (“Praxis”), an accredited Washington State testing facility. Read the results and this entire release at: https://www.financialnewsmedia.com/news-gstr/
Additional industry related developments from around the markets:
The Yield Growth Corp. (OTCQB: BOSQF) (CSE: BOSS) has licensed its patent-pending proprietary technology for extracting key chemical compounds from hemp to its wholly owned subsidiary Yield Botanicals to establish a CBD (cannabidiol) extraction business in the United States.
Yield Botanicals is well positioned to capitalize on substantial growth in the CBD market. Its licensed patent-pending technology shows early promise of significantly increasing the yield of valuable chemical compounds per kilogram of hemp root input during the extraction process, as tested by an independent lab. Yield Botanicals intends to use the same technology as part of the CBD extraction process to increase the yield of CBD from hemp. It also intends to conduct research and development using the technology to create a water-soluble CBD for beverages and to create a CBD nano-emulsion to enhance transdermal bioavailability of topical products. Yield Botanicals also intends to conduct further research regarding a non-toxic plant-based surfactant it has identified to enable creation of clean CBD products.
The Supreme Cannabis Company, Inc.’s (OTCQX: SPRWF) (TSX: FIRE) 7Acres has launched a proprietary strain: Jack Haze. As 7Acres’ first sativa-dominant strain, Jack Haze delivers high tetrahydrocannabinol content with a terpinolene forward profile. Jack Haze is one of the few cultivars available with this dominant cannabis terpene, delivering a complex aroma with notes of citrus, pine and warm spice. True to its scent, Jack Haze offers a crisp, zesty, evergreen flavour. In October, 2018, 7Acres went to market with four core stains that were selected for their strong sensory characteristics. As it develops new genetics in house, 7Acres continues to prioritize subjective quality.
“Jack Haze’s novel name pays homage to the well-known Jack Herer strain. This cultivar’s expression possesses a unique haze profile with a classic, sweet sativa smell and strong visual appeal,” commented John Fowler, chief advocacy officer and founder. “As we develop and introduce unique strains, we further differentiate 7Acres’ high-end flower offering and continue to achieve premium pricing across Canada.”
OrganiGram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) has received Health Canada’s approval for the licensing of 17 additional cultivation rooms under the Cannabis Regulations. The new cultivation rooms represent approximately 15,000 kilograms/year of increased target production capacity. These are the first 17 rooms licensed within the company’s phase 4B expansion and now bring the company’s Moncton facility to annualized licensed capacity to a target of 76,000 kg.
MedMen Enterprises Inc. (OTCQX: MMNFF) (CSE: MMEN) announces expiration of HSR waiting period for proposed acquisition of Pharmacann. The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired with respect to Medmen Enterprises Inc.’s proposed acquisition of PharmaCann LLC. The expiration of the waiting period under the HSR Act satisfies one condition needed to close the transaction, which is expected to be completed by the end of calendar year 2019, subject to customary closing conditions.
“Today marks a monumental day for the cannabis industry,” said Adam Bierman, Medmen co-founder and chief executive officer. “We hope this will pave the way for other companies in what has become a highly acquisitive and dynamic industry.”
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press release issued above by GreenStar Biosciences Corp. by the company. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
CannabisNewsWire Editorial Coverage: A desire to move away from smoking may be fueling growth in the edible cannabis products.
Sproutly Canada Inc. (CSE: SPR) (OTCQB: SRUTF) (FSE: 38G) (SRUTF Profile) is developing new technology to manufacture cannabis edibles and to accurately measure their active ingredients. Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile) has created a bold new technology to make cannabis’ active ingredients more palatable and absorbable. BevCanna Enterprises Inc. (CSE: BEV) (OTC: BVNNF) is producing white-label products, giving other brands access to the market. HEXO Corp. (TSX: HEXO) (NYSE: HEXO) is meeting its regulatory needs by acquiring other licensed cannabis producers and processors. Valens GroWorks Corp. (TSX.V: VGW) (OTCQX: VGWCF) has created a large and growing…
Read more »
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.
Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that non-affiliated, independent researchers have reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex(TM) immunogene therapy, prevented tumor growth in triple-negative breast cancer (“TNBC”). Currently considered an incurable cancer, there are limited therapeutic options available for TNBC. “The results of the study evaluating TUSC2 for the treatment of triple-negative breast cancer are encouraging,” Genprex Chairman and CEO Rodney Varner said in the news release. “We believe that the data reported in this Nature article by independent researchers supports our belief that TUSC2 may be effective to treat a variety of cancers, including some of the most deadly types of cancer.”
To view the full press release, visit: http://nnw.fm/A7Nn9
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://nnw.fm/GNPX
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
- BMO’s block offering of TGOD’s shares was fully subscribed
- TGOD’s CEO commented on the mutual benefits presented by the Aurora transaction
- Investment interest in TGOD has been heightened following completion of the transaction
In the wake of The Bank of Montreal’s (BMO) completion of a block trade of Aurora Cannabis (TSX: ACB) (NYSE: ACB) held shares of The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF), leadership is reportedly pleased to see that 28.8 million overhanging shares remaining from that transaction have been successfully placed, predominately with institutional asset managers.
Through a transaction with BMO, a block trade of 4.8 million shares was completed on Friday, September 6, at $2.96, clearing the remaining shares. Approximately 55-65 percent of the total block of shares was placed in the hands of institutional asset managers, with the balance being taken by…
Read more »
NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://nnw.fm/TGODF
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NEW YORK, Sept. 10, 2019 — via NetworkWire – SRAX, Inc. (NASDAQ: SRAX), a digital marketing and consumer data management technology company, today announces it has selected the corporate communications expertise of NetworkNewsWire (“NNW”).
SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.
Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation. BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. To date, there are 15.9 million BIGtoken registered users worldwide.
NNW is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. NNW’s strategies help public and private organizations find their voice and build market visibility. As part of the Client-Partner relationship with SRAX, NNW will leverage its investor-based distribution network of over 5,000 key syndication outlets, various newsletters, social media channels, blogs, and other outreach tools to generate greater brand awareness for the company.
“SRAX understands what consumers want and has created a platform fulfilling the universal desire to have control over one’s own data,” states Sherri Franklin, Director of Client Solutions for NNW. “As the company focuses on expanding its market reach, we will execute a corporate communications campaign that places its strategy and accomplishments in front of the investment community.”
About SRAX, Inc.
SRAX, Inc. (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels. Monetizing its data sets, SRAX is growing multiple recurring revenue streams through its various platforms. Through the BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data thereby offering everyone in the Internet ecosystem choice, transparency, and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury, and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform. For more information on SRAX, visit www.srax.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets, (3) enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit: https://www.NetworkNewsWire.com.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com
TORONTO, Sept. 10, 2019 – Canopy Rivers Inc. (the “Company” or “Canopy Rivers“) (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, is pleased to share that its portfolio company Herbert Works Ltd. (“Herbert Works“) has received its research and development (R&D) licence from Health Canada to develop branded cannabis-infused beverages.
“This announcement represents a significant milestone for Herbert Works as the company continues to move quickly toward the development of exceptional and widely appealing THC-infused beverages,” said Narbe Alexandrian, President and CEO of Canopy Rivers. “It’s a timely achievement, as the next wave of cannabis legalization in Canada will unlock these new product offerings in a matter of months. We believe that Herbert Works is in a prime position to capitalize on the growth opportunities that ‘Cannabis 2.0′ presents for consumers that are eager to try cannabis in different formats.”
Herbert Works’ mission is to combine advanced technology with its knowledge and appreciation of the experience-enhancing properties of cannabis to create products specifically designed around consumers’ many lifestyle needs. Canopy Rivers currently holds 23% of the equity of Herbert Works on a fully diluted basis (excluding a control warrant). For more information regarding Canopy Rivers’ investment in Herbert Works, please refer to the Company’s annual information form dated July 15, 2019 (“AIF“) filed with the Canadian securities regulators and available on the Company’s profile on SEDAR at www.sedar.com.
About Canopy Rivers:
Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.
Forward-Looking Statements
This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Canopy Rivers with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding: Herbert Works’ ability to develop exceptional, widely appealing THC-infused beverages; the expectation that the next wave of cannabis legalization will unlock new product offerings in a matter of months; management’s belief that Herbert is in a prime position to capitalize on the growth opportunities presented by ‘Cannabis 2.0’; and expectations for other economic, business, and/or competitive factors.
Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Canopy Rivers believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of Canopy Rivers. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; changes in Herbert Works’ ability to develop THC-infused beverages; Herbert Works’ actual ability to capitalize on growth opportunities; changes in consumer preferences and demands and the product offerings available to consumers; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in Canopy Rivers’ AIF, filed with the Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Canopy Rivers has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Canopy Rivers does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
Two Prestigious Research Centers Report PBI’s PCT Platform Delivers Superior Results for Protein Biomarker Discovery Studies from Preserved Cancer Biopsy Tissue Samples
SOUTH EASTON, MA, Sept. 10, 2019 — via NEWMEDIAWIRE – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”) is a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and other industries. The Company announced today the publication of two scientific journal articles, led by independent teams of scientists in China and Australia, reporting excellent results with PBI’s Pressure Cycling Technology (“PCT”) platform in processing preserved formalin-fixed paraffin-embedded (“FFPE”) and fresh frozen biopsy tissue samples for discovery and elucidation of cancer biomarkers and potentially for use in clinical diagnostics based upon these markers. The Chinese team from Westlake University (Hangzhou, China) purchased their first two PCT platforms in 2017 and subsequently purchased four additional PCT systems. The Australian Proteome of Human Cancer (“ProCan”) team bought their first PCT system in 2016 and have subsequently added five more PCT platforms.
FFPE preserved tissue samples are an invaluable resource for retrospective studies of disease progression and response to therapy, because the disease outcome associated with the tissue and patient’s treatment history are known. Effective studies on these sample sets can accelerate discoveries of new therapies, drugs, and preventive strategies. FFPE has been long-established as the most common technique worldwide for the preservation of tissues for later study. Archival repositories exist that contain a total of millions to a billion or more FFPE tissue samples. However, the analysis of FFPE samples has historically been problematic. FFPE preservation techniques were designed for permanence and stability – hence it is challenging to reverse this fixation and to liberate and extract the important biomolecules relevant as cancer biomarkers. Significantly, both publications cited here, together with other publications (See PBI Website), now report excellent results using the PCT sample preparation platform for comprehensive and reliable extraction and presentation of important proteins for analysis, from both FFPE and fresh frozen tissue samples.
Mr. Richard T. Schumacher, President and CEO of Pressure BioSciences, commented: “It is estimated (Nature volume 448, pages 959–962, 23 August 2007) that well over one billion archival FFPE tissue samples exist in pathology and other laboratories worldwide. We believe there are millions of new FFPE tissue samples processed and stored each year. These samples offer the promise of unveiling invaluable information that can lead to the development of new treatments, cures, and preventive measures for cancer and many other diseases. However, up to now, it has been very difficult to extract this information from biomolecules in FFPE samples.”
Ms. Roxana McCloskey, Director of Marketing and Sales at PBI, said: “We believe that our PCT platform is establishing itself as the method of choice for the superior extraction of potential biomarkers and their presentation for the effective proteomic analyses that will propel the growth of this huge market. We expect this exciting, now proven application of our PCT Platform for protein biomarker discovery in fresh frozen and FFPE biopsy samples to manifest itself in increased instrument sales starting in the second half of 2019.”
The global cancer biomarkers market alone is expected to exceed more than US $157 Billion by 2022 (MarketWatch – January 8, 2019).
In their publication High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification, Professor Tiannan Guo, Laboratory Director at Westlake University, explained: “We developed the PCT-SWATH/DIA method of coupling pressure cycling technology for sample preparation with a high throughput mass spectrometry workflow, to analyze FFPE tissue proteomes. We showed that our workflow is a robust and reproducible proteomic method to analyze FFPE tissues from both bulk tissue and tiny biopsy samples as well as sectioned tissue slices.”
Dr. Guo continued, “We believe that the vast reservoirs of historical FFPE tissue samples accumulated in biobanks worldwide offer enormous potential using our methods for biomarker discovery, by leveraging thepracticality and superiority of PBI’s PCT sample preparation platform for maximizing the diversity and abundance of results from FFPE samples (over even fresh frozen samples), followed by mass spectrometry analysis in the PCT-SWATH/DIA workflow.”
Professor Phil Robinson, Co-Director of ProCan, stated: “The key to clinical application of tissue-based proteomics is to adapt to the practical requirements of clinical workflow. Our results from FFPE tissues following PCT sample preparation are consistent with other reports showing that high quality data can be generated and that the scale and scope of quantifiable proteins is comparable to that obtained from fresh frozen tissues.”
Professor Robinson continued: “After samples are collected, tissue lysis and digestion protocols must be rapid, efficient, reproducible and broadly applicable to tissues of different kinds and from different source laboratories. In addition, the methodology should be adaptable for integration of robotics to facilitate high throughput where possible. ProCan has instituted the use of pressure cycling technology (PBI Barocyclers) to achieve consistent and superior lysis and digestion of tissue samples.” (Addressing the challenges of high-throughput cancer tissue proteomics for clinical application: ProCan®).
About Westlake Institute for Advanced Study (now Westlake University)
Westlake Institute for Advanced Study (“WIAS”) is a non-profit research institute dedicated to the advancement of natural sciences and the frontiers of engineering disciplines. Located in the beautiful Cloud Town of Xihu District, Hangzhou, China, WIAS strives to represent the scientific strength of China, to influence the nation’s future, and to promote inclusive development and progress. WIAS, now grown into Westlake University, aims at establishing a top-level research-oriented global university. At WIAS, scientific knowledge and technological advancement are utilized to have a real-life impact on the world and to benefit human beings. Leading talent with innovative spirit and capabilities are trained to become the driving force of China’s development.
About ProCan
The Australian Cancer Research Center Foundation International Centre for the Proteome of Cancer (“ProCan”) is located in newly renovated laboratory facilities at the Children’s Medical Research Institute (“CMRI”) near Sydney, Australia. The goal of ProCan is to analyze over 70,000 cancer samples from all over the world over the next 5 years, with over 10,000 samples completed to date. This will enable a better understanding of cancer, as well as provide a means of personalized precision diagnosis and treatment, giving clinicians the information needed to decide on the best option for each individual patient. CMRI is an official collaborator of the US National Cancer Institute’s Cancer Moonshot initiative, with a key objective to accelerate what would normally take ten years of cancer research to completion in five years.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., CBD Oil and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.
For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.
Investor Contacts:
Richard T. Schumacher, President and CEO
(508) 230-1828 (T)
Nathan P. Lawrence, Ph.D., Senior Advisor
(508) 230-1829 (F)
Point Roberts, WA and Delta, BC – September 9, 2019 (Investorideas.com Newswire) Investorideas.com, a leading investor news resource covering hemp and cannabis stocks releases a snapshot reporting on the Nevada cannabis market and how specifically, Las Vegas is drawing in more consumers and driving more businesses.
In recent sector news it’s been reported that Nevada’s cannabis industry has given more than $100 million in taxes and fees to the state for the first time since recreational marijuana became legal in 2017.
For the fiscal year 2019, dispensaries, cultivators, laboratories and producers have paid over $109 million, according to a September 4, 2019 release from the Nevada Dispensary Association.
NDA says that $99.18 million was paid in taxes, up nearly $25 million from 2018.
“These sales and tax figures are a milestone that should be celebrated by the people of Nevada,” said Riana Durrett of the Dispensary Association. “It shows that the public and visitors to Las Vegas from around the nation are becoming more comfortable purchasing cannabis and the industry is improving its ability to serve the public.”
Las Vegas is also now home to one of the preeminent cannabis conferences, MJBizCon, which is one of the largest gatherings of cannabis business professionals. Ranked as the fastest-growing trade show in the United States, it has grown to over 27,000 attendees since it started in 2012, with an expected 35,000 attendees for the upcoming show taking place December 11-13, 2019 at the Las Vegas Convention Center in Las Vegas.
Global Payout Inc. (OTC: GOHE) and its wholly owned subsidiary MTrac Tech Corporation announced that the Company has expanded its Las Vegas operations office by acquiring office space directly adjacent to the office MTrac has utilized as the hub for its operational team for more than a year.
The significant growth surge the Company has experienced this year onboarding and servicing some of the largest retail and delivery service companies in the cannabis industry has led the Company to strategically add talented new members to its operations support team at a steady, yet effective rate over the last several months. As a result, the Company was thrilled to take advantage of an opportunity that became available to them to acquire additional office space in the adjoining unit to their current office.
“Growth is always an exciting thing to experience as a company,” said Global Payout COO, David Flores. “The core of our team has been intact since we first began our mission of cornering the payment processing sector in the cannabis industry over a year ago, and they have done a phenomenal job managing and contributing to this impressive influx of business. However, as we continue to expand, and as the overall demand for our solution continues to push towards new heights, it is critical that our team is able to successfully meet the needs and demands of a growing client base to ensure that our pledge for exceptional service is never compromised. This expansion provides us with much-needed flexibility to sensibly and efficiently add key members to our operational support staff who are vital in managing the day-to-day responsibilities involved with running our business effectively.”
“The location of the MTrac office is strategic for our headquarters, only a few miles from the airport, adjacent to the Las Vegas strip and in a prime real estate location near the new stadium. Recent renovations were done to the building and MTrac will have a live demo area where clients can come experience the ease of the system in the coming months.”
Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNHF), a leading vertically-integrated Nevada cannabis company, recently announced that it served an average of 2,027 customers per day in August at an average ticket of $90.25 from the Planet 13 Las Vegas Cannabis Entertainment Complex.
“The highly competitive Las Vegas market ‘The SuperStore’ continues to dominate based on the strength of the customer experience and the unique entertainment it offers,” said Bob Groesbeck, Co-CEO of Planet 13. “Over the rest of the year we will continue to rollout new and exciting restaurants, stores and attractions allowing customers to eat, shop, and play all under one cannabis inspired roof.”
The company also recently reported second-quarter revenues of $16.5 million, up by 275% year-over-year.
Green Growth Brands Inc. (CSE: GGB) (OTC: GGBXF) recently announced the closing of its acquisition of Henderson Organic Remedies, LLC (The+Source Henderson), which was previously disclosed on December 14, 2018. The+Source Henderson is the second The+Source dispensary operated by GGB in greater Las Vegas. The productivity of The+Source Henderson is similar to that of The+Source Las Vegas.
“The+Source Henderson has been under our management for the last nine months,” said Peter Horvath, CEO of Green Growth Brands. “In that time, we have grown revenue, transactions and gross margin by double digits. Our ability to significantly improve top performing dispensaries, in a market that has seen a significant uptick in competition, is a testament to our expertise in retail operations.”
The formal acquisition of the company brings GGB’s Las Vegas assets to two The+Source locations, one production facility, two cultivation facilities and seven licenses to operate dispensaries awarded by the Nevada Department of Taxation.
Green Thumb Industries Inc. (CSE:GTII) (OTC: GTBIF), a leading national cannabis consumer packaged goods company and owner of Rise and Essence retail stores, recently reported its financial results for the second quarter ended June 30, 2019.
Second quarter 2019 revenue increased 228% year-over-year to $44.7 million while quarter-over-quarter revenue increased 60%, a record sequential growth for GTI. Revenue growth was driven by organic growth across the Company’s consumer products and retail businesses, strategic acquisitions and increased store traffic.
“We are pleased to report another solid quarter of positive yet disciplined momentum with record revenue and positive adjusted operating EBITDA as our strategic plan delivers on operating efficiencies from scale. Continued execution of key priorities such as the closing of Integral Associates, accelerated store openings, and expanded distribution of our brand portfolio sets us up well for the future,” said GTI Founder and Chief Executive Officer, Ben Kovler.
“We are deep in the chapter of maximizing the levers in our business to drive long-term operational performance that delivers value for our shareholders and the communities in which we operate,” Kovler continued. “We are focused on optimizing our wholesale and retail businesses, integrating our acquisitions, and further strengthening compliance across the organization. We are pleased to see many of these efforts are already bearing fruit as we head into the second half of 2019 and I want to thank our team for all of their hard work.”
On June 5th, GTI successfully completed the acquisition of Integral Associates LLC, with integration efforts and synergies progressing on schedule. The acquisition added two cultivation and processing facilities in Las Vegas, supporting expanded wholesale distribution of GTI’s branded products portfolio in Nevada.
Following the closing of the acquisition of Integral Associates on June 5th, the company’s co-founders Armen and Alex Yemenidijian joined GTI as President and Director, respectively. Armen was the co-founder and CEO of Integral Associates, Nevada’s leading operator and was previously the Chairman of the Board and Chief Executive Officer of Tropicana Las Vegas Hotel & Casino, Inc. and Chairman of the Board and Chief Executive Officer of Metro-Goldwyn-Mayer Inc.
Las Vegas has been well known for its tourism industry and as a greater number of tourists and locals begin to feel more comfortable with the legal cannabis market, and as the market evolves and becomes more efficient, the city and state are creating a huge draw for the cannabis sector. Whether it’s already established MSO’s or celebrity endorsed businesses such as Mike Tyson’s Ranch, Vegas is now starting to bear the fruits of a maturing cannabis industry and many are taking note, just waiting to take a bite.
For investors following cannabis stocks, Investor Ideas has created a stock directory of publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX Marijuana/Hemp Stocks
About Investorideas.com – News that Inspires Big Investing Ideas
https://www.investorideas.com/About/
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Follow us on Cannabis Social Media
https://www.facebook.com/Investorideaspotcasts/
https://twitter.com/MJInvestorIdeas
https://www.instagram.com/potcasts_investorideas/
Download our Mobile App for iPhone and Android
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
Disclosure: this news article featuring GOHE is a paid for news release on Investorideas.com – third party (two thousand) More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
TORONTO, Sept. 9, 2019 – Canopy Rivers Inc. (“Canopy Rivers” or the “Company“) (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, is pleased to announce that, as of the opening of the markets today, its class A subordinated voting shares will begin trading on the Toronto Stock Exchange (the “TSX“) under the ticker symbol “RIV”. This milestone was achieved within less than one year of Canopy Rivers’ initial go-public transaction. No further action is required by existing shareholders.
“We are proud to join a class of issuers that includes many reputable domestic and international companies,” said Narbe Alexandrian, President and CEO of Canopy Rivers. “We believe that graduating to the TSX will improve awareness about Canopy Rivers and enhance liquidity for our shareholders and other market participants.”
On September 24, 2019, Canopy Rivers will participate in the TSX market open ceremony.
About Canopy Rivers:
Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.
Forward-Looking Statements
This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Canopy Rivers with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding: the trading of the Company’s class A subordinated voting shares on the TSX; the benefits of graduating to the TSX; and expectations for other economic, business, and/or competitive factors.
Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Canopy Rivers believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of Canopy Rivers. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; changes in the timing and process for listing on the TSX; the actual impact of the Company’s TSX listing; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in Canopy Rivers’ annual information form dated July 15, 2019, filed with the Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Canopy Rivers has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Canopy Rivers does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
- Study compared Caliper Foods’ proprietary, patent-pending water-soluble cannabinoid technology, Caliper CBD, with CBD in a carrier oil
- Observed total bioavailability of Caliper water-soluble CBD was 4.5 times greater than CBD in a carrier oil
- Higher cannabinoid absorption was observed for Caliper CBD within 15 minutes compared to the maximum absorption of CBD in oil in 45 minutes.
TORONTO and DENVER, Sept. 9, 2019 – The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) (US:TGODF), a leading producer of premium certified organic cannabis, and Caliper Foods (formerly Stillwater Foods), a best-in-class provider of water-soluble cannabinoid products, are pleased to unveil the results of a preliminary human pharmacokinetic (“PK“) study of Caliper CBD, Caliper Foods’ proprietary tasteless and odourless water-soluble powder that can be added to almost any food or beverage.
TGOD intends to commercialize organic cannabinoid dissolvables in Canada beginning in December 2019 under the TGOD-Infusers line of premium cannabis products. The Company has already developed novel fast-acting formulations leveraging this technology with its lineup of organic teas, shots, chewables, and ready-to-drink beverages. In the US, Caliper Foods plans to release Caliper CBD, its own line of precision-dosed CBD dissolvables, this fall.
For this study, half of the participants were administered 30mg of Caliper Foods’ water-soluble CBD powder in 8oz of water while the other half received 30mg of CBD dispersed in MCT oil. Blood samples were drawn at pre-determined times over six hours. Early data shows that the group that received Caliper CBD demonstrated faster onset within 15 minutes, with higher concentrations achieved at 15 minutes compared to the maximum concentration achieved at 45 min with the CBD in oil formulation, and a 4.5-fold higher observed total bioavailability. The CBD was largely eliminated from the body after about 6 hours for both Caliper CBD and CBD oil subjects, and a more rapid reduction was observed with the Caliper CBD subjects after 45 minutes.
Following this promising initial study, TGOD and Caliper Foods will shortly conduct a confirmatory Clinical Phase 1A PK study that will test the Caliper CBD technology formulated into TGOD’s planned portfolio of products including beverages, teas, Infusers, and capsules. The study will be conducted in collaboration with a leading US academic institution.
“We are delighted with these PK results as they confirm the enhanced bioavailability and consistent absorption rates of our proprietary ingredient technology, which can infuse both CBD and THC. This study confirms that consumers absorb 4.5 times more CBD with Caliper CBD than with CBD in MCT oil,” commented Keith Woelfel, Director of R&D at Caliper Foods. “Our R&D team is working closely with TGOD on the next phase of the clinical study, which, if it confirms the PK results in additional product forms, will make Caliper Foods’ and TGOD’s product suites highly differentiated in terms of substantiated quality.”
“We are thrilled with the results of this preliminary PK study which demonstrate the consistency and precision of Caliper Foods’ proven proprietary technology which is already available in Colorado and which TGOD will commercialize in Canada. Based on this early data, Caliper CBD provides a higher and faster absorption level when compared with CBD-infused oil, which opens a number of possibilities for both the medical and adult-use markets. Patients and consumers are increasingly informed and savvy, and we plan to seize on the market demand for organic CBD and THC-infused products backed by data-driven science and clinical evidence,” commented Dr. Rav Kumar, Chief Science Officer of TGOD. “We are enthusiastically awaiting our Clinical Phase 1A PK results in time for Cannabis 2.0 in Canada.”
Caliper Foods’ technology consists of a suite of zero-calorie, fast-acting, water-soluble solutions that can simply and easily infuse cannabinoids into beverages, food, and other consumer goods. It is formulated to quickly absorb into the bloodstream with a predictable onset and offset, allowing these products to offer a consistent, controlled, and safe experience. While cannabinoids are naturally fat-soluble and tend to have a bitter taste, Caliper Foods’ ingredient technology eliminates the need for fat molecules to speed absorption or added sugar to mask the bitterness. As a result, it enables healthier, better-tasting products with no additional fat, sugar, or artificial flavours.
TGOD has an exclusive agreement with Caliper Foods to license the Caliper CBD’s ingredient technology, as well as other proprietary beverage and food technologies and formulations related to cannabinoid-infused consumer packaged goods within Canada and distribute to certain international jurisdictions outside of the United States.
About The Green Organic Dutchman Holdings Ltd.
The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US: TGODF) is a publicly traded, premium global organic cannabis company, with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic hemp CBD oil operations in Canada, and through its wholly owned subsidiary HemPoland distributes premium hemp CBD oil in the EU. The Company grows high quality, certified organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned capacity of 219,000 kgs and is building 1,643,600 sq. ft. of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark.
TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.
For more information on The Green Organic Dutchman Holdings Ltd., please visit www.tgod.ca.
About Caliper Foods
Caliper Foods is a functional foods company specializing in the processing, manufacturing, and distribution of soluble cannabinoid-infused consumer packaged goods and ingredients. The company’s business-to-consumer arm (Caliper Consumer Goods) produces and sells it own line of dissolvable, hemp-derived CBD-infused products. Its initial CBD product, Caliper CBD, will be launching nationwide in the Fall of 2019. The company’s business-to-business arm (Caliper Commercial Ingredients), produces a proprietary suite of application-specific formulations of water-soluble hemp-derived CBD that meet the quality control and documentation needs of experienced CPG experts. The company also has a relationship with Stillwater Brands, maker of some of Colorado’s leading THC- and CBD-infused edibles brands, including Ripple dissolvable cannabinoids, Stillwater Gummy Supplements, and Stillwater Teas & Coffee.
Forward-Looking Information Cautionary Statement
This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward looking statements in this release includes, but is not limited to, statements about future clinical studies, statements about future product development, statements about the offering of any particular products by the Company in any jurisdiction and statements regarding the future performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.
Facility Expansion Remains on Schedule to Increase Capacity and Further Improve Efficiencies of Scale
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce that effective September 6, 2019 it has received Health Canada’s approval for the licensing of 17 additional cultivation rooms under the Cannabis Regulations.
The new cultivation rooms represent approximately 15,000 kg/yr1 of increased target production capacity. These are the first 17 rooms licensed within the Company’s Phase 4B expansion and now brings the Company’s Moncton facility to annualized licensed capacity to a target of 76,000 kg1.
The licenses are valid until March 27, 2020 and subject to terms and conditions.
“Once again, we are pleased to receive licensing approval consistent with our expectations and the streamlined process we have experienced to date. Our Phase 4 facility expansion remains on schedule to meet growing demand and further contribute to efficiencies of scale,” explains Greg Engel, CEO, Organigram.
As a result of this approval, cannabis plants will be moved into these new rooms on a rolling basis commencing immediately. The Company anticipates harvesting product from these new rooms by the end of November assuming normal cultivation timelines. After drying and other post-harvest processing (including packaging) dried flower from these additional rooms is expected to be available for sale to patients and customers in the Company’s fiscal quarter ending February 29, 2020.
Substantial construction of the entire Phase 4B stage remains on schedule for completion in September 2019 and the Company also anticipates submitting the licensing amendment for the remaining 16 Phase 4B cultivation rooms later this month.
The perimeter of Phase 5 of the Company’s expansion, which will include an edibles and derivative product facility and more extraction capacity, is also planned for this Health Canada licensing submission.
About Organigram Holdings Inc.
Organigram Holdings Inc. is a NASDAQ Global Select and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.
Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Company, Ankr Organics, Trailer Park Buds and Trailblazer. Organigram’s primary facility is located in Moncton, New Brunswick and the Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).
This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors that could change anticipated timelines for filing of submissions, processing times, capacity utilization, cultivation and in market timelines; including risks as disclosed in the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR (see www.sedar.com) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. We seek safe harbor.
1 The forward looking estimate of target production capacity, once fully operational, is based on a number of material factors and assumptions. Please see the Company’s most recent MD&A available on SEDAR at www.sedar.com and EDGAR at www.sec.gov and the disclaimer at the end of this release.
For Investor Relations enquiries, please contact:
Amy Schwalm
Vice President, Investor Relations
Amy.Schwalm@organigram.ca
(416) 704-9057
For Media enquiries, please contact:
Ray Gracewood
Senior Vice President, Marketing and Communications
rgracewood@organigram.ca
(506) 645-1653
LOS ANGELES, Sept. 9, 2019 — SRAX, Inc. (NASDAQ: SRAX), a digital marketing and consumer data management technology company, today announces it has entered into new partnerships with major consumer packaged goods (CPG) brands to launch BIG Rewards™, a new feature of SRAX’s consumer-managed data marketplace, BIGtoken. BIG Rewards™ enables marketers to engage BIGtoken’s nearly 16 million users to participate in brand research and exclusive offers, effectively expanding BIGtoken’s commercial capabilities, and solving data problems across the digital marketing and advertising industry.
Through BIG Rewards™, U.S. BIGtoken users will have the ability to earn bonus points for participating in exclusive promotions with specific brands and retailers, and for taking part in brand research. Users can participate by first completing a short survey about a brand, retailer, or product; they can then scan their receipts for related product purchases to earn bonus BIGtoken points. BIG Rewards™ not only provides users with the opportunity to benefit from discounts on their everyday purchases, it also enables users to get paid immediately on those earnings.
“This initiative represents one of many ways we can provide BIGtoken offerings beyond data targeting,” says Kristoffer Nelson, COO of SRAX and co-founder of BIGtoken. “BIG Rewards™ addresses the need for brand research during a time when consumers’ behavior towards brands are in constant flux. BIGtoken is quickly becoming a one-stop shop, enabling brands to utilize the BIG platform for research and build digital media campaigns around deep insights.”
“This commercial expansion will be extremely valuable in the shopper marketing space especially as data regulation continues to grow,” says George Stella, Vice President of SRAX Shopper, SRAX’s shopper marketing vertical. “Increased data regulation will make it challenging for media partners to activate against the current state of data. BIG Rewards™ allows brands to position themselves as advocates for their customers’ privacy. It also enables the brands to create future-proof insights while driving verified purchases of products at their retail locations.”
To download the BIGtoken application, please visit: https://bigtoken.app.link/pressdownload. BIG can also be accessed via the web by visiting my.bigtoken.com.
About SRAX
SRAX, Inc. (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels. Monetizing its data sets, SRAX is growing multiple recurring revenue streams through its various platforms. Through the BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data thereby offering everyone in the Internet ecosystem choice, transparency, and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury, and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform. For more information on SRAX, visit www.srax.com.
About BIGtoken
BIGtoken, built by SRAX (NASDAQ: SRAX), is a consumer data management and distribution system. BIG is the first consumer-managed data marketplace where people can own and earn from their data. Through a transparent platform and consumer reward systems, BIG offers consumers choice, transparency, and compensation for their data. Participating consumers earn rewards, and developers are able to build pro-consumer online experiences on top of the BIG platform. The system also provides advertisers and media companies access to transparent, verified consumer data to better reach and serve audiences. For more information on BIGtoken, visit www.bigtoken.com.
Safe Harbor Statement
This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Words or expressions such as “anticipate,” “plan,” “will,” “intend,” “believe” or “expect'” or variations of such words and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including, without limitation, statements made with respect to expectations of our ability to increase our revenues, satisfy our obligations as they become due, report profitable operations and other risks and uncertainties, as set forth in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of SRAX and are difficult to predict. SRAX undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACTS:
Kirsten Chapman
LHA Investor Relations
415-433-3777
srax@lhai.com
Corporate Communications:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com
Data and artificial intelligence-driven discovery services company Predictive Oncology (NASDAQ: POAI) provides predictive models of tumor drug response to improve patient outcome. A recent article discussing the company reads, “Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based road map for therapy. . . . In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM) patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.”
To view the full article, visit: http://nnw.fm/eGbU8
About Predictive Oncology Inc.
Predictive Oncology (formerly Precision Therapeutics Inc.) operates through its three business units: Helomics, TumorGenesis and Skyline Medical. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient-treatment decisions, by providing an evidence-based road map for therapy. In addition to its proprietary precision-oncology platform, Helomics offers boutique CRO services that leverage its TruTumor, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient-specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NEW YORK, Sept. 06, 2019 — via NetworkNewsAudio – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) announces the availability of a NetworkNewsAudio publication titled, “Innovative Drug-Delivery Systems Benefit Patients and Businesses.”
To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/J4u6k
To read the full editorial, visit: http://nnw.fm/4P2sn
Drugs play an essential role in treating anything from a mild headache to life-threatening disease — and everything in between. While effectiveness of drugs is what most often captures the spotlight, that effectiveness is closely associated with the drug-delivery technology used, and innovation in this space may have a huge impact on how successful a drug can be.
Lexaria Bioscience Corp.’s DehydraTECH(TM) may be the most novel form of drug delivery discovered in decades. Fatty acids used in the technology mask the smell and taste of the drug and potentially greatly reduce stomach upset. This allows it to be added to all sorts of foods and drinks — oral delivery — without relying on artificial flavors or loads of sugar to mask a drug. This is useful not just for nicotine but for other pharmaceuticals as well.
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its disruptive delivery technology, which promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates, more rapid delivery to the bloodstream, and important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
About NetworkNewsAudio
NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) can assist your company by cutting through the overload of information in today’s market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.
For more information, visit: www.NetworkNewsAudio.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com
NEW YORK, Sept. 06, 2019 — via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled “Gene Therapy Treatments Offer Hope for Cancer Patients.”
To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/Bqm4W
To read the full editorial, visit: http://nnw.fm/k9gI7
Recent developments in gene therapy hold out hope for the treatment of a wide range of diseases, including fatal lung cancer.
Imagined in the 1970s and first carried out in the 1980s, gene therapy is one of the newest frontiers in medicine. The therapy involves the delivery of nucleic acids, the tiny building blocks of life, into human cells. This can rewrite the genetics of cells, removing parts that are causing ill health and strengthening those that fight disease.
A number of companies have emerged with the aim of applying gene therapy to specific diseases. For example, Genprex Inc. (NASDAQ:GNPX) specializes in tackling non-small cell lung cancer through its developmental drug Oncoprex(TM).
About Genprex Inc.
Genprex Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell-signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. Visit the company’s web site at www.genprex.com or follow Genprex on Twitter at twitter.com/genprex, Facebook at facebook.com/genprexinc and LinkedIn at linkedin.com/company/genprex.
About NetworkNewsAudio
NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) can assist your company by cutting through the overload of information in today’s market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.
For more information, visit: www.NetworkNewsAudio.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com
Canopy Rivers (TSX.V: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, on Thursday announced that it has received final approval to list its class A subordinated voting shares on the Toronto Stock Exchange (“TSX”). Per the update, the shares will begin trading on the TSX under the ticker symbol “RIV” on September 9 at the opening of markets. The company’s subordinated voting shares will be delisted from the TSX Venture Exchange in conjunction with listing on the TSX.
To view the full press release, visit: http://nnw.fm/0DvYp
About Canopy Rivers Inc.
Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem. For more information, visit the company’s website at www.CanopyRivers.com.
NOTE TO INVESTORS: The latest news and updates relating to CNPOF are available in the company’s newsroom at http://nnw.fm/CNPOF
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
- Lexaria Bioscience is an innovator in the field of bioavailable lipophilic active compounds, and it is working to make consumption of certain products through oral ingestion a viable alternative to inhalation
- A particular focus of the company’s technology is to ensure that cannabinoids can enter the blood stream at speeds comparable to smoking and can be used in a discrete manner
- Cannabis-infused beverage sales are expected to surpass $1.4 billion by 2024, marking a nearly 15-fold increase over 2018 levels
Drug bio-delivery technology innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has launched online commercial delivery of the cannabis industry’s most advanced water-soluble multi-spectrum hemp oil in a powdered format, making high-quality hemp oil with cannabidiol (CBD) readily available to meet the beverage infusion needs of consumers in the United States.
The company’s August 22 announcement (http://nnw.fm/Ql3vI) states that its ChrgD+ product is powered by Lexaria’s proprietary DehydraTECH(TM) technology for rapid CBD delivery to the user’s bloodstream within…
Read more »
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://nnw.fm/LXRP
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
TORONTO, Sept. 4, 2019
- Improves revenue and margin potential by recovering offtake of TGOD’s premium organic cannabis
- Boosts TGOD’s institutional ownership ahead of potential NASDAQ listing
- Unlocks opportunities for new relationships with third party partners
TORONTO, Sept. 4, 2019 – The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) (US:TGODF) comments on the recent transaction between Aurora Cannabis (“Aurora”) (TSX:ACB) and a syndicate of Canadian banks. The block trade was executed on September 3 after market close. A total of 28.8 million shares were exchanged at a negotiated price of $3.00 per unit. The Edmonton-based company still retains a large number of TGOD warrants equivalent to approximately 5% of the Company’s fully diluted shares.
This transaction significantly improves TGOD’s revenue and gross margin mix due to the repatriation of TGOD’s premium organic cannabis previously earmarked for Aurora under the Investor Rights Agreement (the “Agreement“) between the parties. The Agreement included a revenue sharing model with Aurora which would have lowered TGOD’s average selling price and margins.
“Aurora has been an excellent partner during TGOD’s initial development phase; their investment played an important role in our success. The relationship added significant value across multiple areas of the business, including the initial design and construction of our Canadian facilities,” commented Brian Athaide, CEO of TGOD. ” This is the right next step in the relationship as both companies mature and our respective strategies evolve. It also improves TGOD’s revenue and margin potential on the sale of our premium organic cannabis,” added Athaide.
About The Green Organic Dutchman Holdings Ltd.
The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US: TGODF) is a publicly traded, premium global organic cannabis company, with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic hemp CBD oil operations in Canada, and through its wholly owned subsidiary HemPoland distributes premium hemp CBD oil in the EU. The Company grows high quality, certified organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned capacity of 219,000 kgs and is building 1,643,600 sq. ft. of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark.
TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.
For more information on The Green Organic Dutchman Holdings Ltd., please visit www.tgod.ca.
Forward-Looking Information Cautionary Statement
This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward looking statements in this release includes, but is not limited to, statements about expectations regarding listing on NASDAQ and registration under the U.S. Exchange Act, statements about future profit margins and revenue, statements about future research, development and innovation by the Company, statements about the offering of any particular products by the Company in any jurisdiction and statements regarding the future performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.
NetworkNewsWire Editorial Coverage: Recent developments in gene therapy hold out hope for the treatment of a wide range of diseases, including fatal lung cancer.
Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) is focused on using gene therapy to tackle lung cancer, developing new drugs that can be used alongside existing treatments. Pfizer Inc. (NYSE: PFE) has created a state-of-the-art research center focused on gene therapy treatments, which it uses for illnesses including cancer. Gilead Sciences Inc. (NASDAQ: GILD) is using biotechnology to tackle a range of challenging diseases, including HIV and hepatitis. Sarepta Therapeutics Inc. (NASDAQ: SRPT) is developing 20 different genetic treatments for a wide range of diseases. Merck & Company Inc. (NYSE: MRK) has treatments in development for both prostate and lung cancer, offering further hope for those…
Read more »
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced anticipated milestones and future guidance on its clinical development programs, manufacturing and strategy for bringing its lead drug candidate, Oncoprex™ immunogene therapy, to market.
These anticipated milestones and future guidance are incorporated into the latest update of the company’s corporate presentation, which can be found on the company’s website.
“These milestones emphasize our commitment to developing potentially life-changing gene technologies for cancer patients who need them most,” said Rodney Varner, Chairman and Chief Executive Officer of Genprex. “We continue to dedicate our efforts toward developing Oncoprex for non-small cell lung cancer (“NSCLC”) and we believe that achievement of these milestones will enable us to advance our gene therapy platform and position us to bring our drug candidate to commercialization.”
Anticipated milestones and future guidance:
2H 2019
- Establish scalability parameters of new, optimized manufacturing method for lipid nanoparticle delivery system as part of new Genprex research and development program
- Complete protocol for Oncoprex + immunotherapy clinical trial
- Prepare and file IND for Oncoprex + immunotherapy clinical trial
- Determine clinical site selection, expansion strategy and contract with clinical sites for Oncoprex + erlotinib clinical trial
1H 2020
- Complete manufacturing scale-up to support trial site expansion and commercial-scale development
- Complete preparation of lipid nanoparticle delivery system and TUSC2 DNA plasmid for clinical expansion
- Contract with new clinical trial sites for Oncoprex + immunotherapy clinical trial
- Begin enrolling patients at new clinical sites for Oncoprex + immunotherapy clinical trial
In addition to the milestone updates, Genprex also unveiled in its updated corporate presentation, an overview of the limitations to current NSCLC treatment and a swimmer plot demonstrating results to date of its Phase I/II clinical trial administering Oncoprex in combination with erlotinib against NSCLC. Genprex also recently launched a new interactive timeline on its website where visitors can follow the company’s success since its inception.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, please visit the company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our stated milestones and our ability to advance the clinical development, manufacturing and commercialization of our product candidates, and the effects of Oncoprex on cancer. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include our ability to achieve our stated milestones, the timing and effect of our achieving those milestones, and of other factors, on the clinical development, manufacturing and commercialization of our product candidates, the presence and level of TUSC2’s effect on cancer, the timing and success of our clinical trials and planned clinical trials of TUSC2 and Oncoprex™ and our other potential product candidates and the timing and success of obtaining FDA approval of Oncoprex™ and our other potential product candidates. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Genprex, Inc.
(877) 774-GNPX (4679)
Investor Relations
GNPX Investor Relations
(877) 774-GNPX (4679) ext. #2
investors@genprex.com
Media Contact
Genprex Media Relations
Kalyn Dabbs
(877) 774-GNPX (4679) ext. #3
media@genprex.com
- Helomics is collaborating with the University of Pittsburgh School of Medicine to study the use of artificial intelligence to improve clinical decision making for ovarian cancer patients. More than 22,000 women are diagnosed with ovarian cancer in the U.S. each year.
- Entered an agreement with Interpace Diagnostics Group Inc. (IDXG) and Helomics to develop products to diagnose and assess the risk for thyroid cancer as well as provide appropriate therapeutic recommendations. The treatment market for thyroid cancer is expected to reach $2.1 billion by 2025.
- Skyline Medical has received its first order for four STREAMWAY machines to be sold to local hospitals in India. The Indian healthcare industry is estimated at more than $100 billion, with the nation’s medical device industry valued at more than $6 billion.
- Helomics signed a collaborative research agreement with Pittsburgh-based molecular imaging company, ChemImage, to expand personalized medicine to prostate cancer diagnosis and treatment.
- TumorGenesis and partner 48Hour Discovery received the Alberta Innovates grant for development of novel cancer treatments.
Predictive Oncology Inc. (NASDAQ: POAI) is a data and artificial intelligence-driven discovery services company that provides predictive models of tumor drug response to improve patient outcome. Predictive Oncology harnesses the power of artificial intelligence, collaborating with the pharmaceutical, diagnostic and biotech industries to develop highly customizable assessment methods for patients, which can lead to much more effective treatments.
Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of…
Read more »
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
TORONTO, Sept. 3, 2019 – The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) (US:TGODF), a leading producer of premium certified organic cannabis, is pleased to announce that it has obtained approval from Health Canada, under the Cannabis Regulations, to expand operations into its new hybrid greenhouse located in Hamilton, Ontario. The 123,000 square foot state-of-the-art facility will serve to increase TGOD’s premium organic cannabis production as it expands its sales in Canada.
TGOD’s hybrid greenhouse is the fruit of years of research and development. From its cutting-edge climate control systems and water recapture systems to LED lighting, it combines the latest technologies with natural elements such as living soil and natural sunlight. This organic growing facility has a much better environmental footprint and lower waste than traditional large-scale cannabis growing.
“We are thrilled to start using this purpose-built hybrid greenhouse as we ramp up our production of premium organic cannabis, an underserved segment of the market,” commented Brian Athaide, CEO of TGOD. “Our team pioneered the concept of growing organic cannabis at scale; this hybrid greenhouse has been artfully designed for organic cultivation, allowing us to reliably produce clean, safe and non irradiated cannabis.”
The new facility is the third phase of TGOD’s Hamilton site, measuring 166,000 square feet with an annual production capacity of 17,500 kgs of premium organic cannabis. In line with its commitment to sustainability, TGOD aims to have the building LEED certified.
The Company is also seeking an eGMP certification for this facility in order to allow for global exports, as laws and regulations permit.
About The Green Organic Dutchman Holdings Ltd.
The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US: TGODF) is a publicly traded, premium global organic cannabis company, with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic hemp CBD oil operations in Canada, and through its wholly owned subsidiary HemPoland distributes premium hemp CBD oil in the EU. The Company grows high quality, certified organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned capacity of 219,000 kgs and is building 1,643,600 sq. ft. of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark.
TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.
For more information on The Green Organic Dutchman Holdings Ltd., please visit www.tgod.ca.
Forward-Looking Information Cautionary Statement
This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward looking statements in this release includes, but is not limited to, statements about future facility construction, statements about future production capacity, statements about the achievement of certain certifications in connection with its facilities, statements about the receipt of any regulatory permits or licences, statements about the offering of any particular products by the Company in any jurisdiction and statements regarding the future performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.
Despite the broader weakness in the cannabis sector, TGOD stock has gained almost 10% so far in August. Here are some of the key developments this month for The Green Organic Dutchman (TSX:TGOD) (OTCQX:TGODF).
Application to List on the Nasdaq
Over the course of the past year or so, cannabis company The Green Organic Dutchman has made plenty of interesting moves, and earlier this month, it made its most important move so far. Earlier this month the company submitted its application to be listed on the NASDAQ and that could prove to be an eventual game changer for the company if it is approved. The ticker sign is going to be TGOD if its application is approved.
However, the company added that it will continue to trade on the Toronto Stock Exchange. The NASDAQ exchange lists some of the world’s biggest corporations and listing there will give The Green Organic Dutchman access to a much bigger pool of investors.
Moreover, listing on an exchange like NASDAQ can also result in the flow of big money into something like TGOD stock. If the approval is granted, the company is going to play in the big leagues.
The company published its financial results for Q2 2019 earlier this month and managed to record a 20% growth in its revenues from the first quarter. That is a highly impressive performance for the company, and the Chief Executive Officer Brian Athaide stated that TGOD has got highly positive reviews with regards to its organic premium cannabis.
The company is also a powerhouse when it comes production capabilities, and The Green Organic Dutchman has projected that when operating at full tilt it could produce as much as 219,000 kilos a year. On the other hand, it has also signed important deals, one of the most important being the extraction services deal with Neptune Wellness Solutions (TSX:NEPT) (NASDAQ:NEPT).
TGOD is going to supply 230,000 kilos of hemp and cannabis to Neptune over the course of three years. The company is certainly moving in the right direction, and investors should watch out for TGOD stock.
